Symbiotec Pharmalab made its stock market debut on September 1, 2026, following strong investor interest in its initial public offering (IPO). The pharmaceutical and biotechnology company’s shares were listed at ₹988 apiece on the National Stock Exchange (NSE), matching the IPO issue price. On the Bombay Stock Exchange (BSE), the stock opened at ₹978.20, representing a decline of about 1% from the issue price.
The muted debut came despite the company’s IPO receiving an exceptionally strong response from investors. The ₹1,757-crore issue was subscribed more than 70 times during the bidding period, reflecting significant demand across investor categories.
Symbiotec Pharmalab, based in Madhya Pradesh, operates in the pharmaceutical and biotechnology sector and focuses on research-driven manufacturing, including active pharmaceutical ingredients (APIs). The company has manufacturing capabilities spanning organic chemistry, biotechnology and complex injectables.
The listing has attracted attention from investors watching India’s expanding pharmaceutical manufacturing sector. While the initial performance was below expectations indicated by grey-market trends, market participants will now focus on the company’s business performance, growth plans and future earnings.
The company’s market capitalisation at listing was around ₹6,285 crore.
